“出海”交易金额突破千亿美元，研发管线覆盖全价值链，中国医药创新在“量”上已然爆发，但“质”的飞跃仍需要穿越靶点同质化的迷雾。今年以来，中国创新药领域亮点频频。官方数据显示，2025年上半年，国家药品监督管理局（NMPA）已批准1类新药43个（按通用名计），其中国产新药40个，进口新药3个。2022年至2024年，全年获批数量分别为19个、40个和48个。今年上半年获批总量已超越去年全年半数，...
Source Link“出海”交易金额突破千亿美元，研发管线覆盖全价值链，中国医药创新在“量”上已然爆发，但“质”的飞跃仍需要穿越靶点同质化的迷雾。今年以来，中国创新药领域亮点频频。官方数据显示，2025年上半年，国家药品监督管理局（NMPA）已批准1类新药43个（按通用名计），其中国产新药40个，进口新药3个。2022年至2024年，全年获批数量分别为19个、40个和48个。今年上半年获批总量已超越去年全年半数，...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.